Treatment News : Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 9, 2012

Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells

by Tim Horn

CROI 2012 Researchers have shown for the first time that it is possible to target and interrupt the mechanism by which HIV remains hidden and unreachable by antiretroviral (ARV) drugs, according to highly anticipated study results presented Thursday, March 8, at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle. Though no people living with HIV participating in the study saw their virus eradicated as result of the experiment, the findings paint an optimistic picture for scientists in pursuit of a cure for HIV.

After protease inhibitors were approved in the mid-1990s, researchers hoped that the advent of combination ARV therapy would be potent enough to burn out HIV infection over time. It soon became apparent, however, that no matter how strong the drugs are and how long a person’s virus level remains undetectable, HIV can still hide out inside dormant cells and bring the infection flaring back to life once ARV meds are stopped.

Therapies initially studied to reawaken these cells succeeded in forcing them to purge their HIV payload, but the therapies caused too much immune system inflammation. In other words, while they “turned on” the dormant cells, they also created so many susceptible uninfected CD4 cells that the ARV drugs couldn’t protect them. 

What was needed, scientists argued, was a drug that could force out the HIV hiding within these cells without activating immune system cells at the same time. One such approach that has gained a lot of attention in recent years is the inhibition of histone deacetylase (HDAC), an enzyme believed to play a key role in maintaining HIV inside long-lived resting cells.

Douglas Dieterich  

David Margolis, MD, at his lab at the University of North Carolina School of Medicine in Chapel Hill.
©Charles L Harris for UNC School of Medicine


An early experiment with an HDAC inhibitor called Depakote (valproic acid), conducted by David Margolis, MD, of the University of North Carolina and Chapel Hill and his colleagues, proved promising. But another round of studies, reported a few years later in 2005, failed to show that valproic acid significantly affected the recalcitrant reservoirs of dormant HIV-infected cells.

Margolis and his team then set their eyes on another HDAC inhibitor, Zolinza (vorinostat), a cancer chemotherapeutic that in 2009 was found to awaken dormant HIV-infected cells, both in laboratory cell cultures and in blood taken from people on ARV therapy. A year later, Margolis’s group announced their plans for a clinical trial involving people living with HIV.

The clinical trial enrolled six HIV-positive men averaging 45 years old. All study volunteers had been on therapy for an average of four years, had undetectable viral loads and had stable CD4 cell counts in excess of 500.

The study’s first step was to harvest resting CD4 cells from the patients, which was needed to test HIV-RNA levels—a marker of viral activity—inside the cells. From there, the cells were exposed to Zolinza, which confirmed that the HDAC inhibitor had the ability to increase HIV-RNA levels.

The second step was to explore whether or not the Zolinza dose selected for the study—400 milligrams (mg)—had an effect on histone acetylation, the cellular process needed to turn on HIV expression in the dormant cells. Margolis reported that there was a more than twofold increase in this activity within eight hours of receiving a single dose of Zolinza.

The final step was to check Zolinza’s ability to increase HIV-RNA levels in the pools of resting CD4 cells obtained after vorinostat, compared with pre-treatment measurements. Margolis reported that there was an average 4.8 increase in all six patients, which ranged from a 1.5-fold increase in one patient to a 10-fold increase in another.

The researchers also failed to find a statistically significant increase in blood-based HIV-RNA levels, suggesting that while Zolinza succeeded at turning on HIV expression in the cells, it did not have an unfavorable effect of increasing viral load.

Margolis also noted that any adverse effects reported during the study were mild and that none appeared to be related to Zolinza treatment.

“This study provides first proof of concept, demonstrating disruption of latency, a significant step toward eradication,” Margolis concluded. “The effort to fully understand the potential of such approaches to influence both the natural history and clinical management of HIV infection deserves urgent and accelerated investigation.”

Search: Zolinza, vorinostat, HDAC, SAHA, Margolis, CROI, cure, eradication, latency, dormant, Seattle

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

  comments 16 - 27 (of 27 total)     << < previous

Steve, san francisco, 2012-03-30 16:08:11
Agree with all the comments about the cure being closer than ever, because I think that's a matter of fact now. Another breakthrough announcement was made recently on the cure front, look up 'antibody pgt 128', which is effective at curing 70 percent of hiv strains "Although the antibody does not provide a solution to all HIV infected people around the world, scientists are optimistic about finding a potential lifetime cure because of the success of this research."excerpt from Cornell Daily Sun!

a herbert, Vancouver, Canada, 2012-03-29 10:54:24
I am now poz over 29 years, CD4s range 800 to 1200, undetectable and have been on ARVs since they became available. I have been active in AIDS organizations from the beginning but now focusing on issues related to Long Term Survivors. This particularl includes side effects from long term consumption of new and powerful meds plus the question of early on-set of age-related illnesses.

ws, hartford, 2012-03-28 21:12:09
I have seen many hopefuls in the past 30yrs, does anyone remember heating the blood to kill the virus in italy? It all sounds good but haven't they all? Seeing is believing and will we have another attorney commercial for this one down the road? I think they're looking for funding and hope is still far away. I do wish it were true and works but I have seen so many hopefuls with different approaches.

phantom, , 2012-03-25 07:38:09
I find any inkling of hope to be of a miracle. Lots of research is going on and lots of great ideas.. I agree with many it seems so close to finding the cure not to be giving up hope.

Michael, Barcelona, 2012-03-19 10:28:17
John said "I do not understand why this reservoir is deemed to be such a problem for those living with HIV." First, this reservoir means that you can't clear the virus and you will have to take drugs for life and second, HIV in reservoirs also causes overstimulation of the immune system, which leads to the development of diseases linked with older age (cancer, for instance).

J.S., S.C., 2012-03-17 17:11:03
With all of these new pathways to finding a cure emurging I feel like something will come about pretty quickly lord willing and finally take down the HIV virus it's 30 years over due.

chrissie, SA, 2012-03-16 06:49:11
What is amazing is back anf forth of medical researches , when do we see a gunuine,conclusive eradication of HIV ?

Shortstack, Pittsburgh, 2012-03-14 17:06:44
This sounds like good news, but I have some reservations! Once someone starts on this"Chemo", how long will this have to be taken? It just sounds like another drug to add to the Regiment, indefinitely!

yago, Barcelona, 2012-03-14 06:16:54
Great news!, and I'm completely agree with, "HIV infection deserves urgent and accelerated investigation", specially now that the end seems to be closer than ever.

Bob, , 2012-03-14 00:05:19
John, even if HIV were a "chronic manageable condition" the reservoir would be a major problem for social reasons. Unless you can fix the ancient prejudice against certain people who are "sick", curing this diease so we don't continue to be marginalized is sufficient reason in and of itself. BTW, if you think we can just "eliminate stigma", I've got a beach house in Arizona I'd like to sell you...

John, Minneapolis, 2012-03-12 22:03:33
I do not understand why this reservoir is deemed to be such a problem for those living with HIV. If the reservoir is inactive, not replicating, it is not doing any harm. So long as one adheres to their arvs, the latent reservoir need not be a problem.

steve, , 2012-03-09 19:58:13
this is amazing news!

comments 16 - 27 (of 27 total)     << < previous

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.